GT Biopharma Inc. - GTBP STOCK NEWS

GT Biopharma (NASDAQ: GTBP) has been granted two new patents by the USPTO for its TriKE® technology, which targets antigens, including HIV, enhancing the clinical pipeline of therapies. Patent No. 11,098,100 covers TriKE proteins for any antigen, while Patent No. 11,098,101 focuses on HIV antigens. This development secures broad intellectual property rights for the company, supporting its ongoing clinical trials, such as the promising GTB-3550 TriKE® Phase I trial for acute myeloid leukemia and myelodysplastic syndromes, as stated by CEO Anthony Cataldo.

GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company, announced that key executives will present at two upcoming healthcare conferences. The H.C. Wainwright 23rd Annual Global Healthcare Conference is set for September 13, 2021, featuring a pre-recorded corporate presentation and a live panel on NK therapy at 1:00 PM ET. The Baird Global Healthcare Conference will follow on September 15, 2021, at 8:30 AM ET. Interested participants can schedule one-on-one meetings with the management team via conference organizers.

GT Biopharma, Inc. (NASDAQ: GTBP) announced the promotion of Dr. Gregory Berk to President of Research & Development and Chief Medical Officer. Dr. Berk, previously Chief Medical Officer, will oversee key functions in discovery, development, and manufacturing of therapeutics. The company is transitioning GMP manufacturing from the University of Minnesota to Cytovance Biologics. GT Biopharma is developing GTB-3550, a trispecific NK cell engager, currently in Phase 1 for treating relapsed AML and high-risk MDS, with interim clinical data to be presented at the ESMO Annual Congress.

GT Biopharma (NASDAQ: GTBP) provided a business update for Q2 2021, highlighting its clinical advancements with the TriKE^® platform. Significant interim results from the Phase I/II trial of GTB-3550 TriKE^® showed a 57% reduction in AML/MDS cancer cell burden. The company also announced a strategic partnership with Dr. Jeffrey S. Miller and was added to the Russell 2000^® Index. Additionally, GT Biopharma secured $16M from warrant exercises to further develop its technologies.

GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company, will conduct a conference call on August 13, 2021, at 8:30 a.m. EST to discuss second quarter 2021 financial results and business updates. Interested parties can join by calling 1-877-870-4263 (U.S.) or 1-412-317-0790 (international). A replay of the call will be accessible for 30 days via the company's website. GT Biopharma focuses on developing therapeutics based on its proprietary TriKE™ NK cell engager platform, aimed at enhancing the immune system's response to cancer.

GT Biopharma (NASDAQ: GTBP) announced positive preclinical results for its B7H3 TriKE product candidate, GTB-5550, aimed at cancer treatment. Evaluated in several preclinical models, GTB-5550 effectively enhanced NK cell killing of various cancer cell types, particularly those overexpressing B7H3 found in cancers like non-small cell lung cancer and breast cancer. The company is preparing for an Investigational New Drug (IND) filing with the FDA and has achieved an important development milestone according to CEO Anthony J. Cataldo.

GT Biopharma, Inc. (NASDAQ: GTBP) announced it has raised over $16 million from the exercise of warrants, part of a $27 million financing completed in February 2021. This funding strengthens the company's financial position, enabling further development of its drug candidates, including GTB-4550, GTB-5550, and GTB-6550. GTB-3550 is currently in FDA Phase 1 Clinical Trial with 12 patients treated, and results are expected to be published in September 2021. The company has approximately $40 million in its treasury for ongoing drug development.

GT Biopharma announces a sponsored research agreement with Dr. Jeffrey Miller from the University of Minnesota to enhance the clinical development of its TriKE™ therapeutics for cancer treatment. The contract, valued at $2,074,686, spans two years with quarterly payments and allows GT Biopharma exclusive rights to patentable inventions. TriKE™ has shown effectiveness in reviving NK cells and reducing cancer cell burdens without significant toxicities in clinical trials. Positive results were reported in the GTB-3550 TriKE™ trial, including a 57% reduction in cancer cell burden in some patients.

GT Biopharma, Inc. (NASDAQ: GTBP) announced that CEO Tony Cataldo will present at Sir Anthony Ritossa's Global Family Office Investment Summit in Monaco from June 30 to July 2, 2021. The summit is known for bringing together prestigious family offices and investors from over 30 countries, representing more than $4.5 trillion in wealth. GT Biopharma specializes in immuno-oncology therapeutics, utilizing its proprietary TriKE™ NK cell engager technology platform to enhance patients' natural killer cells for cancer treatment. For more information, visit gtbiopharma.com.